DENVER, Dec. 12, 2012 /PRNewswire/ -- Accelr8 Technology
Corporation (NYSE MKT: AXK) announced today that its common stock
has been approved by The NASDAQ Stock Market, LLC for listing on
the NASDAQ Capital Market. The Company expects to commence
trading on NASDAQ under the ticker symbol "AXDX" on Wednesday, December 26, 2012. Until such
date, the Company's common stock will continue to be traded on NYSE
MKT (formerly known as NYSE Amex) under its current ticker symbol,
"AXK".
About Accelr8
Accelr8 Technology Corporation (www.accelr8.com) is focused on
developing and commercializing innovative instrumentation for the
rapid identification and antibiotic susceptibility testing of
infectious pathogens. The Company's BACcelTM
platform utilizes a proprietary culture-free process with both
genomic and phenotypic detection technologies that decrease time to
result while maintaining high sensitivity and
specificity.
Disclaimer Regarding Forward-Looking Statements
Certain statements in this news release may be "forward-looking
statements" within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended. Statements regarding future prospects
and developments are based upon current expectations and involve
certain risks and uncertainties that could cause actual results and
developments to differ materially from the forward-looking
statement, including those detailed in the Company's filings with
the SEC. The Company does not undertake an obligation to
publicly update or revise any forward-looking statements, whether
as a result of new information or future events.
SOURCE Accelr8 Technology Corporation